{
  "pmid": "56789012",
  "title": "Meta-analysis of SGLT2 Inhibitors in CKD",
  "year": 2024,
  "population": {
    "description": "Patients with chronic kidney disease stage 3-4",
    "sample_size": 3400
  },
  "endpoints": [
    {
      "endpoint_phrase": "eGFR decline rate",
      "point_estimate": -2.5,
      "confidence_interval": {
        "lower": -3.2,
        "upper": -1.8
      },
      "p_value": 0.0001
    },
    {
      "endpoint_phrase": "progression to dialysis",
      "point_estimate": 0.65,
      "confidence_interval": {
        "lower": 0.52,
        "upper": 0.81
      },
      "p_value": 0.0003
    },
    {
      "endpoint_phrase": "cardiovascular death",
      "point_estimate": 0.78,
      "confidence_interval": {
        "lower": 0.63,
        "upper": 0.97
      },
      "p_value": 0.02
    },
    {
      "endpoint_phrase": "acute kidney injury",
      "point_estimate": 0.85,
      "confidence_interval": {
        "lower": 0.72,
        "upper": 1.01
      },
      "p_value": 0.06
    }
  ],
  "study_design": "meta-analysis"
}